CTLA4 and colitis: irAE are a common side effect in patients undergoing immune checkpoint blockade for cancer, with colitis being the most serious and sometimes fatal irAE associated with anti-CTLA4 treatment.27 Surprisingly, there is a paucity of translational models that mimic anti-CTLA4-related clinical adverse events.